Streetbeat News

Analyst Ratings

ABBV

A significant bullish stance has been taken on AbbVie (NYSE:ABBV) by a large investor or institution, as indicated by unusual options trading activity. The overall sentiment of these big-money traders is split between 53% bullish and 46% bearish. The whales have been targeting a price range from $105.0 to $175.0 for AbbVie over the last 3 months. The price of ABBV is up 0.89% at $150.96, and RSI indicators suggest the stock may be overbought.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 8:02 pm

HAL

A significant investor has taken a bearish stance on Halliburton (NYSE:HAL), with 80% of detected trades being bearish and 20% bullish. The trades include 5 puts totaling $287,921 and 5 calls totaling $375,870. Whales have been targeting a price range from $36.0 to $45.0 for Halliburton over the last 3 months. The current price of HAL is up 1.75% at $40.48. Analysts from Morgan Stanley, Stifel, HSBC, and Raymond James have maintained their positive ratings on Halliburton with price targets ranging from $45 to $50.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 8:02 pm

CLBT

Over the past 3 months, 4 analysts have published their opinion on Cellebrite DI (NASDAQ:CLBT) stock, with 3 being bullish, 1 somewhat bullish, and none bearish. The average 12-month price target for the stock is $9.5, with a high of $11.00 and a low of $7.00. This average price target has increased by 26.67% over the past month.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 8:00 pm

GPI

In the last quarter, Group 1 Automotive (NYSE:GPI) received 2 bullish, 1 somewhat bullish, and 1 somewhat bearish analyst ratings. The company's average 12-month price target has increased by 18.48% from the previous average of $236.33 to $280.0.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 8:00 pm

VZIO

In the last quarter, VIZIO Holding (NYSE:VZIO) received mostly bullish ratings from 8 analysts, with an average 12-month price target of $11.25, a decrease of 6.25% from the previous average price target of $12.00.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 8:00 pm

CRNX

Over the past 3 months, 5 analysts have published their opinion on Crinetics Pharmaceuticals (NASDAQ:CRNX) stock. The analysts have an average price target of $38.2 versus the current price of Crinetics Pharmaceuticals at $16.62, implying upside. This average price target has increased by 9.14% over the past month.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 8:00 pm

TOST

In the last quarter, Toast (NYSE:TOST) received 6 bullish, 1 somewhat bullish, and 4 indifferent analyst ratings. Over the past 3 months, 11 analysts have offered 12-month price targets for Toast, with an average price target of $26.05, a high of $31.00, and a low of $22.00. The average price target has increased by 6.02% over the past month.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 8:00 pm

DICE

Nine analysts have provided ratings for DICE Therapeutics (NASDAQ:DICE) in the last quarter, with two being bullish and seven indifferent. The average price target is $50.78, which is higher than the current price of $47.55. This average represents a 14.66% decrease from the previous average price target of $59.50.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 8:00 pm

PODD

TD Cowen analyst Josh Jennings has maintained an 'Outperform' rating on Insulet (NASDAQ:PODD), but lowered the price target from $350 to $300.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 7:58 pm

MARA

Compass Point analyst Chase White has maintained a 'Buy' rating on Marathon Digital Holdings (NASDAQ:MARA) but lowered the price target from $21 to $20.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 7:53 pm